SPOTLIGHT -
Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC
Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.
Read More
Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer
Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.
Dr. Klein on Precision Medicine for Prostate Cancer
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.
Dr. Klein on Gene Mutations in Prostate Cancer
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)